Navigation Links
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
Date:10/30/2008

thy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing.

ANA773 is an orally administered prodrug of a novel TLR7-specific agonist. Results from preclinical pharmacology studies have shown that ANA773 can elicit desired immune responses and that the profile of response can be modulated by both dose and schedule of administration. Results of completed 13-week GLP toxicology studies have shown that with every-other-day dosing of ANA773, immune stimulation of a magnitude believed to confer therapeutic potential can be achieved without adverse toxicology findings. The immune stimulation observed with every-other-day dosing of ANA773 in monkeys included induction of interferon-alpha and interferon dependent responses at levels that are sustained over 13 weeks of dosing.

Clinical Need and Market Opportunity in HCV Infection

Chronic HCV infection is a serious public health concern affecting approximately 3.2 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 29, 2015   For the seventh year running, ... assess their overall digital maturity called the Multichannel ... companies are not maturing fast enough. While it,s true ... numerous ways overall and customers are increasingly "digital natives", ... digital customer engagement.  ...
(Date:6/26/2015)... Lawrence, MA (PRWEB) , ... June 26, 2015 ... ... the U.S. Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... referred to as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. ...
(Date:6/26/2015)... ... June 26, 2015 , ... DNA Genotek, ... of OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that it has awarded grants ... Gut Microbiome Grant Program. The company has awarded its OMNIgene®•GUT fecal/stool ...
(Date:6/25/2015)... 25, 2015 Current asthma medications, which ... or by dilating the airways, can stop working ... Brigham and Women,s Hospital and Harvard Medical School ... targeting certain sensory nerve endings in the lungs ... online in the journal Neuron on ...
Breaking Biology Technology:Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 3Targeting Nerve Endings To Curb Allergic Asthma 2Targeting Nerve Endings To Curb Allergic Asthma 3Targeting Nerve Endings To Curb Allergic Asthma 4Targeting Nerve Endings To Curb Allergic Asthma 5
... in research funding, TORONTO, May 21 ... Thoracic Society (ATS), the world,s leading,professional organization for ... expansion of their research partnership in,pulmonary fibrosis. CPF ... awards for researchers in the United States pursuing ...
... Daiichi Sankyo Co., Ltd. announced today,that it has entered ... Pharma AG, a German biotechnology company focusing on research ... will purchase 100 percent of the stock and make ... for the,company. Closure of the transaction is subject to ...
... ALTO, Calif., May 20 Parents of children with,autism often ... do something to cause the disorder? Could it be genetic? ... there new medications or therapies that,might alleviate some of my ... teachers of children with,autism will have a unique opportunity to ...
Cached Biology Technology:Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010 2Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010 3Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 2Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 3First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 2First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 3
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/18/2015)... This report analyzes the worldwide markets for ... Segments, which includes Immunoassay Analyzers and Reagents: Enzyme Immunoassay ... Systems, and Nephelometric Immunoassay Systems. The report provides separate ... , Japan , Europe ... Latin America , and Rest of World. Annual ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... span, prevent the spread of the disease, and is cost ... report in the February 10 issue of the New England ... of a two-paper series in NEJM on the value of ... used different data and methods than another study by VA, ...
... St Andrews have developed a new method of delivering ... which is cheap and powerful, could have important implications ... technology has huge potential for novel developments in the ... in this area. The new method -which involves a ...
... 1 million deaths worldwide every year and several research ... that result in the initiation and progression of these ... function of one gene, called Adenomatous Polyposis Coli (APC) ... innermost layer of the colon (called the epithelium) and ...
Cached Biology News:Boosting HIV screening can increase survival and is cost effective 2New methods of gene delivery using lasers 2Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer 2
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... The Model 111 mini IEF cell ... isoelectric focusing (IEF) using polyacrylamide or agarose ... chamber and lid, graphite electrodes, casting tray, ... support film for polyacrylamide, 5 sample templates, ...
... is the latest entry in the Biomek line. ... and increased robustness, it can meet the needs ... configured with either one or two pipetting pods. ... sets the standard for flexible laboratory solutions to ...
... By incorporating a wide range of next-generation ... sets a new standard for flexible laboratory ... handling including pipetting, dilution, dispensing, and ... thats as powerful and flexible as it ...
Biology Products: